LS-106

LS-106 is a potent, orally bioavailable EGFR inhibitor effective against C797S triple-mutant variants, including EGFR19del/T790M/C797S (IC50=2.4 nM) . It demonstrates superior in vitro kinase inhibition compared to Osimertinib, induces apoptosis, and shows significant in vivo antitumor efficacy in xenograft models harboring these resistant mutations.